Lesogaberan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lesogaberan
Lesogaberan.svg
Lesogaberan ball-and-stick model.png
Names
IUPAC name
((R)-3-Amino-2-fluoropropyl)phosphinic acid
Other names
AZD-3355
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.133.162
UNII
Properties
C3H9FNO2P
Molar mass 141.08 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

Lesogaberan (AZD-3355) was[1] an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD).[2] As a GABAB receptor agonist,[3] it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD.[4]

References[edit]

  1. ^ AstraZeneca. "AZD3355". Retrieved 30 December 2011. 
  2. ^ Bredenoord, Albert J. (2009). "Lesogaberan, a GABAB agonist for the potential treatment of gastroesophageal reflux disease". IDrugs. 12 (9): 576–584. PMID 19697277. 
  3. ^ Alstermark; Amin, K; Dinn, SR; Elebring, T; Fjellström, O; Fitzpatrick, K; Geiss, WB; Gottfries, J; et al. (2008). "Synthesis and Pharmacological Evaluation of Novel γ-Aminobutyric Acid Type B (GABAB) Receptor Agonists as Gastroesophageal Reflux Inhibitors". Journal of Medicinal Chemistry. 51 (14): 4315–4320. PMID 18578471. doi:10.1021/jm701425k. 
  4. ^ Brian E. Lacy; Robert Chehade; Michael D. Crowell (2010). "Lesogaberan". Drugs of the Future. 35 (12): 987–992. doi:10.1358/dof.2010.035.012.1540661.